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OPA1 increases the risk of normal but not high tension
glaucoma
P Yu-Wai-Man,1,2 J D Stewart,1 G Hudson,1 R M Andrews,3 P G Griffiths,2
M K Birch,2 P F Chinnery1,4
ABSTRACT
Background Primary open angle glaucoma is
a progressive optic neuropathy characterised by the
selective loss of retinal ganglion cells, pathological optic
disc cupping and visual field defects. The OPA1 gene
encodes an inner mitochondrial membrane protein crucial
for normal mitochondrial function, and pathogenic
mutations cause autosomal dominant optic atrophy by
specifically targeting retinal ganglion cells. This raises the
distinct possibility that more subtle genetic variations in
OPA1 could alter the risk of developing glaucoma.
Methods 137 patients with primary open angle
glaucoma (67 patients with high-tension glaucoma
(HTG), 70 patients with normal-tension glaucoma (NTG))
and 75 controls from the North East of England were
studied. Three single-nucleotide polymorphisms in intron
8 (IVS8+4c/t and IVS8+32t/c) and exon
4 (c.473A/G) of the OPA1 gene were genotyped in the
study group. In addition, the entire OPA1 coding region
was sequenced in 24 individuals with the CT/TT
compound genotype using standard BigDye chemistries.
Results There was no difference in either allele or
genotype frequency for the IVS8+32t/c single-
nucleotide polymorphisms between patients and
controls, but there was a significant association between
the T allele at IVS8+4c/t and the risk of developing
NTG (OR¼2.04, 95% CI¼1.10 to 3.81, p¼0.004), but not
HTG. Logistic regression analysis also confirmed a strong
association between the CT/TT compound genotype at
IVS8+4 and IVS8+32 with NTG (OR¼29.75, 95%
CI¼3.83 to 231.21, p¼0.001).
Conclusions The CT/TT compound genotype at IVS8+4
and IVS8+32 is a strong genetic risk determinant for NTG
but not HTG.
INTRODUCTION
Primary open angle glaucoma (POAG) is the second
most common cause of blindness in developed
countries and accounts for about 10% of all blind
registration in the UK.1 It affects over 60 million
people worldwide, and, with an ageing population,
the prevalence of POAG is expected to increase by
30% in the next 20 years.2 POAG is characterised by
the selective, progressive loss of retinal ganglion
cells (RGCs), leading to structural changes at the
optic nerve head in the form of pathological cupping
and visual field loss. The most significant risk
factors for the development of glaucoma are raised
intraocular pressure (IOP), increasing age, a positive
family history in a first-degree relative and ethnicity
(Black>Hispanic>Caucasian>Asian).3 4 In the
non-glaucomatous population, IOP follows
a normal distribution with a mean of 16.0 mm Hg
and a SD of 2.5 mm Hg, giving a statistical upper
limit of 21.0 mm Hg. About two-thirds of patients
with POAG have IOPs >21.0 mm Hg at initial
presentation, referred to as high-tension glaucoma
(HTG), whereas the remainder with IOPs #21.0
mm Hg are classified as having normal-tension
glaucoma (NTG).3 4
POAG is a complex disease with a strong genetic
component, and multiple susceptibility loci have
been identified in populations from different ethnic
backgrounds.3 5 Four causative genes have been
identified so far: optineurin (OPTN, OMIM 602432)
on chromosome 10p14-15, myocilin (MYOC, OMIM
610652) on chromosome 1q24-25, CYP1B1 (OMIM
601771) on chromosome 2p21-22, and WDR36
(OMIM 609669) on chromosome 5q21-22, but these
account for fewer than 5e10% of patients with
sporadic, adult-onset POAG. Interestingly,
a maternal family history of POAG is 6e8 times
more likely than a paternal family history, which
suggests a possible mitochondrial genetic influ-
ence.6e8 Furthermore, mitochondrial abnormalities
have been identified in patients with POAG, with an
increase in mitochondrial DNA (mtDNA) content
and a reduction in mitochondrial respiratory chain
activities.9 The preferential loss of RGCs in glau-
coma is also a key pathological feature seen in Leber
hereditary optic neuropathy (LHON) and auto-
somal dominant optic atrophy (DOA), the two
most common inherited optic neuropathies. Both
these conditions are the result of mitochondrial
dysfunction; LHON comes from primary mtDNA
mutations affecting the respiratory chain
complexes, and the majority of DOA families have
mutations in the OPA1 gene (3q28-q29), which
codes for an inner mitochondrial membrane protein
critical for mitochondrial maintenance, oxidative
phosphorylation and regulation of apoptosis.10
Two single-nucleotide polymorphisms (SNPs)
within intron 8 of the OPA1 gene (IVS8+4c/t and
IVS8+32t/c) have been linked with an increased
risk of developing POAG in some, but not all,
populations studied.11e15 To further clarify the
influence of OPA1 in modulating susceptibility to
glaucoma, we have performed an analysis of OPA1
SNPs in a well-characterised cohort of patients with
POAG, and in addition reviewed the literature to
compare the strength of the association identified in
other study groups.
METHODS
Patient and control samples
We investigated a well-characterised Caucasian
cohort consisting of 137 patients with POAG
(mean (SD) age¼71.6 (8.0) years) and 75 controls
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(mean (SD) age¼79.3 (4.4) years) from the North East of
England, a region that has been relatively stable in terms of
migratory flux.16 17 The POAG group consisted of 67 HTG
patients with a mean (SD) pre-treatment IOP of 23.1 (2.0) mm
Hg (range 22e28) and 70 NTG patients with a mean (SD) pre-
treatment IOP of 17.7 (2.2) mm Hg (range 13e21). Both cases
and controls underwent a full ophthalmological examination
including: (1) IOP measurement by Goldmann applanation
tonometry, (2) gonioscopy to confirm open drainage angles, (3)
dilated fundal examination, and (4) Humphrey full-threshold
24:2 visual field perimetry. All patients had unequivocal evidence
of glaucoma, with both pathological optic disc cupping and
characteristic visual field defects. HTG patients with IOPs >30
mmHgwere not included in this study. Control subjects were
unaffected spouses of patients with POAG, and other ocular
pathologies were carefully excluded. Genomic DNA was
extracted from whole blood using established methods16 17 and
stored at808C for future molecular genetic investigations, with
prior approval having been obtained from our local research
ethics committee.
OPA1 genotyping
The two SNPs in intron 8 (IVS8+4c/t and IVS8+32t/c) were
genotyped using the following primers to generate a 383 bp PCR
product: (1) forward, 59-TGAAGTTCTTGATGTTCTCTCTG-39;
(2) reverse, 59-ATGGCTAATTTAATCCACTGTTC-39. In the
second phase of this study, the entire coding region of the
OPA1 gene was amplified in 24 individuals with the CT/TT
compound genotype (HTG, N¼10; NTG, N¼12; controls, N¼2),
using a set of 27 M13-tagged primer pairs (available on request).
Genotyping for the c.473A/G SNP located in exon 4 was also
determined for the entire study cohort, using the following
primers to generate a 341 bp PCR product: (1) forward,
59-GGGTTGTCATGAGGATTAAACAA-39; (2) reverse 59-
AAAAATGTCCTGTTTTTCATTGG-39. For all three SNPs (IVS8+
4c/t, IVS8+32t/c and c.473A/G) and the entire OPA1 coding
region, PCR products were purified and sequenced using BigDye
terminator cycle chemistries on an ABI3100 Genetic Analyser
(Applied Biosystems, Warrington, UK). Sequence results were
then compared with the GenBank OPA1 reference sequence
(Accession number AB011139) using SeqScape software v2.1.
mtDNA haplogroups
The mtDNA haplogroup status for both patients and controls
had previously been determined by restriction fragment analysis
of amplified PCR fragments spanning specific informative sites
within the mitochondrial genome.18 Haplogroups K, W, I, V, X
andMwere present in less than 5% of our control population and
these were analysed as a single group.
Statistical analysis
The HardyeWeinberg equilibrium for OPA1 genotypes was
assessed for patients and controls (http://ihg.gsf.de/cgi-bin/hw/
hwa1.pl), and statistical analyses were performed using SPSS v15
statistical software. Allele and genotype SNP frequencies were
compared using the Fisher exact test and c2 analysis, with
Bonferroni correction for multiple comparisons where applicable.
Binary logistic regression was also used for multivariate analysis
of other possible confounding factors that could influence the
risk of developing glaucoma. This form of analysis assumes that
the logarithm of the odds ratio (OR) is a linear function of the
predictor variables included in the model:
LogðP=1 PÞ ¼ B0 þ B1X1 þ B2X2 þ .BnXn
where P is the probability of developing glaucoma, X1, X2.Xn
represent the chosen predictor variables, and B0, B1.Bn are
coefficients reflecting the nature of each predictor.19 The inde-
pendent variables used in our model were: (1) age, (2) gender,
(3) maximum pre-treatment IOP, (4) mtDNA haplogroup and
(5) IVS8+4 and IVS8+32 compound genotype.
RESULTS
Intron 8 SNPs
Both POAG and control groups were in HardyeWeinberg equi-
librium at IVS8+4c/t and IVS8+32t/c. The Tallele at IVS8+
4c/t was over-represented among NTG patients compared with
controls (OR¼2.04, 95% CI¼1.10 to 3.81, p¼0.03), but there was
Table 1 Allele and genotype frequencies for the IVS8+4c/t and IVS8+32t/c OPA1 SNPs
Controls (N[75) Whole group (N[137) HTG (N[67) NTG (N[70)
(A) IVS8+4c/t
Allele p Value p Value p Value
C 131 (87.3%) 222 (81.0%) 114 (85.1%) 108 (77.1%)
T 19 (12.7%) 52 (19.0%) 0.096 20 (14.9%) 0.581 32 (22.9%) 0.030*
Genotype p Valuey p Valuey p Valuey
CC 59 (78.7%) 90 (65.7%) 49 (73.1%) 41 (58.6%)
CT 13 (17.3%) 42 (30.7%) 16 (23.9%) 26 (37.1%)
TT 3 (4.0%) 5 (3.6%) 0.106 2 (3.0%) 0.061 3 (4.3%) 0.025*
(B) IVS8+32t/c
Allele p Value p Value p Value
T 79 (52.7%) 155 (56.6%) 60 (44.8%) 59 (42.1%)
C 71 (47.3%) 119 (43.4%) 0.440 74 (55.2%) 0.666 81 (57.9%) 0.375
Genotype p Valuez p Valuez p Valuez
TT 21 (28.0%) 41 (29.9%) 12 (17.9%) 11 (15.7%)
TC 37 (49.3%) 73 (53.3%) 36 (53.7%) 37 (52.9%)
CC 17 (22.7%) 23 (16.8%) 0.578 19 (28.4%) 0.769 22 (31.4%) 0.566
c2 analysis of all three possible genotypes at yIVS8+4C/T and zIVS8+32T/C.
*Significant p value.
SNP, single-nucleotide polymorphisms.
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no significant difference in allele frequency for the HTG and
whole POAG groups. Similarly, there was a significant difference
in the distribution of the three IVS8+4c/t genotypes for the
NTG group (p¼0.025), but not for the HTG or whole POAG
groups (table 1A). There was no significant difference in either
allele or genotype frequency for the IVS8+32t/c SNP when
comparing all POAG cases, HTG and NTG subgroups with
controls (table 1B).
Compound genotype
Analysis of both IVS8+4c/t and IVS8+32t/c SNPs showed
a significant increased risk of glaucoma in subjects with the CT/
TT compound genotype for the whole POAG group
(OR¼6.98, 95% CI¼1.59 to 30.59, p¼0.003) and NTG group
(OR¼7.55, 95% CI¼1.63 to 35.10, p¼0.004). Although there was
a trend towards a higher risk of HTGwith the CT/TTcompound
genotype (p¼0.013), this was not significant after Bonferroni
correction (table 2). The CT/TT compound genotype was also
not associated with higher pre-treatment IOPs or worse cup to
disc ratios (CDRs), in both the HTG and NTG groups (p>0.05,
data not shown).
Logistic regression
Binary logistic regression confirmed a significantly increased risk
of developing glaucoma with the CT/TT compound genotype
for the whole patient group (OR¼56.52, 95% CI¼5.98 to 533.78,
p<0.001) and those with NTG (OR¼29.75, 95% CI¼3.83 to
231.21, p<0.001), but not for the HTG group (table 3). None of
the mtDNA haplogroups were significant risk factors for glau-
coma. Although haplogroup J was over-represented among NTG
patients compared with controls (p¼0.045), this fell below the
level for statistical significance with Bonferroni correction.
OPA1 haplotype
We sequenced the entire OPA1 coding region of all 24 individuals
with the CT/TT compound genotype at IVS8+4 and IVS8+32
(HTG, N¼10; NTG, N¼12; controls, N¼2), and no previously
described pathogenic mutations were identified. However, all of
them shared the same haplotype, with homozygosity at both the
c.473A/G (p.N158S) and c.2109C/T (p.A703A) SNPs, except
for one NTG patient (figure 1A). The latter was heterozygous for
the c.473A/G and c.2109C/T SNPs, and also had two addi-
tional heterozygous SNPs at c.575C/T (p.A192V) and
Table 2 Compound genotype frequencies for the IVS8+4c/t and IVS8+32t/c OPA1 single-nucleotide polymorphisms
IVS8+4 IVS8+32 Patients Controls p Value* OR 95% CI
(A) Whole group
TT TT 5 (3.6%) 3 (4.0%) 1.000 0.91 0.21 to 3.92
CT TT 22 (16.1%) 2 (2.7%) 0.003* 6.98 1.59 to 30.59
CT TC 20 (14.6%) 11 (14.7%) 0.989 0.99 0.45 to 2.21
CC TT 14 (10.2%) 16 (21.3%) 0.026 0.42 0.19 to 0.92
CC TC 53 (38.7%) 26 (34.7%) 0.563 1.19 0.66 to 2.14
CC CC 23 (16.8%) 17 (22.7%) 0.296 0.69 0.34 to 1.39
(B) HTG
TT TT 2 (3.0%) 3 (4.0%) 1.000 0.74 0.12 to 4.56
CT TT 10 (14.9%) 2 (2.7%) 0.013 6.40 1.35 to 30.40
CT TC 6 (9.0%) 11 (14.7%) 0.316 0.57 0.20 to 1.64
CC TT 7 (10.4%) 16 (21.3%) 0.110 0.43 0.17 to 1.12
CC TC 30 (44.8%) 26 (34.7%) 0.216 1.53 0.78 to 3.01
CC CC 12 (17.9%) 17 (22.7%) 0.483 0.74 0.33 to 1.70
(C) NTG
TT TT 3 (4.3%) 3 (4.0%) 1.000 1.08 0.21 to 5.51
CT TT 12 (17.1%) 2 (2.7%) 0.004* 7.55 1.63 to 35.10
CT TC 14 (20.0%) 11 (14.7%) 0.396 1.46 0.61 to 3.46
CC TT 7 (10.0%) 16 (21.3%) 0.062 0.41 0.16 to 1.07
CC TC 23 (32.9%) 26 (34.7%) 0.818 0.92 0.46 to 1.84
CC CC 11 (15.7%) 17 (22.7%) 0.289 0.64 0.27 to 1.48
*Significant with Bonferroni correction: p<0.008.
Table 3 Logistic regression analysis comparing patients with POAG with controls
Whole group HTG NTG
Predictor variables OR (95% CI) p Value OR (95% CI) p Value OR (95% CI) p Value
mtDNA haplogroupy
H 0.62 (0.26 to 1.50) 0.292 0.97 (0.43 to 2.18) 0.934 0.51 (0.20 to 1.28) 0.151
T 0.42 (0.12 to 1.48) 0.176 0.65 (0.21 to 2.00) 0.457 0.37 (0.10 to 1.45) 0.154
J 3.79 (0.86 to 16.63) 0.077 1.64 (0.34 to 8.05) 0.540 4.42 (1.04 to 18.92) 0.045
U 1.68 (0.50 to 5.62) 0.401 2.02 (0.62 to 6.62) 0.246 1.85 (0.53 to 6.38) 0.332
Others 0.82 (0.24 to 2.82) 0.757 0.65 (0.19 to 2.21) 0.490 0.72 (0.21 to 2.52) 0.609
Compound genotypez
CT/TT 56.52 (5.98 to 533.78) <0.001* 9.91 (1.74 to 56.57) 0.010 29.75 (3.83 to 231.21) <0.001*
Our logistic regression models also incorporated the following predictor variables with the controls acting as the reference group: (1) age, (2) gender, and (3) maximum IOP, except in the HTG
subgroup where maximum IOP was not included;
*Significant with Bonferroni correction: yp<0.01, zp<0.008.
IOP, intraocular pressure; HTG, high-tension glaucoma; mtDNA, mitochondrial DNA; NTG, normal-tension glaucoma; POAG, primary open angle glaucoma.
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c.1608A/C (p.A536A). Further analysis of the non-synonymous
c.473A/G (p.N158S) SNP in our entire study cohort did not
show any statistically significant difference between our patient
and control groups (table 4).
DISCUSSION
This study has identified a strong association between specific
OPA1 polymorphisms at IVS8+4c/t and IVS8+32t/c and the
risk of glaucoma. Subgroup analysis based upon pre-treatment
IOPs further indicated that the susceptibility conferred by these
two SNPs was largely restricted to the NTG group. This is
compatible with the notion that non-IOP-related factors are
probably more important in the pathophysiology of NTG than
of HTG.3 5 The Tallele at IVS8+4 led to a twofold increased risk
of NTG, and, although the IVS8+32 SNP on its own was not
a risk factor, compound genotype analysis suggested a synergistic
influence with the IVS8+4 SNP and identified CT/TT as the
high-risk compound genotype.
To confirm our initial findings, we performed a more rigorous
logistic regression analysis to control for the possible influence of
other variables that might affect the risk of developing
glaucoma, thereby minimising the chance of identifying
a spurious association. The OR for the CT/TT compound
genotype remained highly significant, and was associated with
a 30-fold increased risk of NTG, independent of age, gender,
maximum pre-treatment IOP and mtDNA haplogroup. How-
ever, the CT/TT compound genotype was not associated with
markers of disease severity, either higher pre-treatment IOPs or
worse optic disc cupping, supporting the conclusions of
a previous report.20 MtDNA haplogroup J was also over-repre-
sented among the NTG group compared with controls, although
this became non-significant with Bonferroni correction. Never-
theless, this is an interesting observation given that the mtDNA
background is thought to exert a direct effect on the assembly of
the mitochondrial respiratory chain complexes,21 and
haplogroup J specifically has been linked with an increased risk of
visual loss among Caucasian LHON mutation carriers,22 the
classic example of an inherited mitochondrial optic neuropathy.
We performed a literature review to identify all previous OPA1
glaucoma association studies, including unpublished meeting
abstracts, and there is a consistent lack of association between
the IVS8+4 and IVS+32 SNPs and HTG (table 5). A high-risk
compound genotype for developing NTG was found in two
studies involving British Caucasian subjects11 13 and one Japa-
nese study,23 with the latter reporting a weaker association.
However, no association was identified in other populations of
Asian14 15 24 and African extraction,25 26 possibly indicating that
the influence of OPA1 polymorphisms on NTG is limited to
certain ethnic groups or it has a smaller effect (OR <1.5), not
detectable by the sample size (<100) used in most of these
studies. In this respect, it is worth noting that the control groups
in these studies indicate a marked variation in the frequency of
Figure 1 (A) Shared OPA1 haplotype in
individuals with the IVS8+4 and IVS8+32 CT/
TT compound genotype. (B) Alignment of the
36 amino acids encoded by exon 4, indicating
the poor evolutionary conservation of the
codon altered by the c.473A/G SNP (p.
N158S) in both lower vertebrates and
invertebrates.
Table 4 Allele and genotype frequencies for the c.473A/G OPA1 single-nucleotide polymorphism
Allele Genotype
N A G p Value AA AG GG p Value*
Whole group 137 128 (46.7%) 146 (53.3%) 26 (19.0%) 76 (55.5%) 35 (25.5%)
Controls 75 75 (50.0%) 75 (50.0%) 0.543 19 (25.3%) 37 (49.3%) 19 (25.3%) 0.531
HTG 67 65 (48.5%) 69 (51.5%) 13 (19.4%) 39 (58.2%) 15 (22.4%)
Controls 75 75 (50.0%) 75 (50.0%) 0.813 19 (25.3%) 37 (49.3%) 19 (25.3%) 0.548
NTG 70 63 (45.0%) 77 (55.0%) 13 (18.6%) 37 (52.9%) 20 (28.6%)
Controls 75 75 (50.0%) 75 (50.0%) 0.818 19 (25.3%) 37 (49.3%) 19 (25.3%) 0.613
*c2 analysis of all three possible genotypes at c.473A/G.
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the minor T allele at IVS8+4c/t in different populations:
Caucasian (7e18%), African (2e5%) and Asian (1e2%). Of note,
the three other studies that have found a significant association
between OPA1 and NTG have all identified different high-risk
compound genotypes from the one identified in our study. As
caseecontrol studies are open to several sources of bias which can
be difficult to control, this could be due to a spurious population
stratification effect. Alternatively, association with different
alleles in the same gene can occur when the actual susceptibility
allele is in linkage disequilibrium with the SNPs under
investigation.
What are the possible explanations for the increased risk of
NTG in individuals harbouring the CT/TT compound geno-
type? The majority of pathogenic OPA1 mutations are trunca-
tive (>70%), and the reduction in protein concentration
implicates haploinsufficiency as the underlying process leading to
optic nerve degeneration in DOA.27 Opa1 is a multi-functional
protein and its crucial pro-fusion properties contribute to the
maintenance of a highly interconnected mitochondrial network
within cells.10 It is therefore not surprising that mitochondrial
fragmentation is a prominent feature in fibroblasts cultured from
patients with DOA, with the release of cytochrome c from the
mitochondrial compartment precipitating the onset of apoptotic
cell death.28 29 A recent study has also found murine RGCs to be
more sensitive to the downstream events of mitochondrial
fragmentation and pro-apoptotic stimuli than other neuronal
populations.30 As the IVS8+4 SNP is located within the donor
splice site region, the CT/TT compound genotype may exert an
effect, albeit unproven, on mRNA transcript concentrations,
which would then potentiate RGC loss by disrupting the delicate
balance between mitochondrial fusion and fission. However, the
more pronounced effect seen in NTG compared to HTG clearly
implicates other mechanisms, and additional investigations are
required.
Unlike other association studies, we also sequenced the whole
OPA1 coding region, firstly to exclude the possibility of patho-
genic mutations because DOA is quite often misdiagnosed as
NTG in clinical practice,31 and secondly to explore the possibility
that IVS8+4 and IVS8+32 are actually tagging SNPs in linkage
disequilibrium with another functional OPA1 variant. Except for
one NTG patient, all individuals carrying the CT/TTcompound
genotype shared the same OPA1 haplotype, with homozygosity
at both the c.473A/G (p.N158S) and c.2109C/T (p.A703A)
SNPs, suggesting a common ancestral event. Subsequent analysis
of our entire cohort did not identify any significant difference in
allele or genotype frequency at the poorly conserved, non-
synonymous c.473A/G SNP in exon 4 (figure 1B). However, our
study has not excluded the possibility that the IVS8+4 and IVS8
+32 SNPs are in linkage disequilibrium with another causative
gene in the vicinity of OPA1 or the presence of OPA1 intronic
variants regulating mRNA splicing or transcriptional activity.
The finding of a significant association between the specific
combination of OPA1 polymorphisms and NTG does not imply
causation, and, although biologically plausible, our results require
additional functional confirmation, for example by comparing
the bioenergetics and mitochondrial network morphology of
fibroblasts obtained from patients with and without the high-
risk CT/TT compound genotype. With a rapidly ageing popula-
tion, glaucoma will remain an important cause of visual
morbidity, and a greater understanding of the complex genetic
influences that lead to RGC loss will have important implications
both for the identification and screening of high-risk groups and
in identifying pathophysiological pathways that could be
amenable to therapeutic intervention.
Table 5 Summary of previous studies investigating the role of OPA1 polymorphisms in POAG
Significant association High-risk compound genotype (NTG)
Study* Population HTG N NTG N IVS8+4/+32 Odds ratioy 95% CI
[11,12] Caucasian No 90 Yes 163 CT/TC 6.25 2.67 to 14.59
[13] Caucasian N/A e Yes 61 CC/CC 2.71 1.31 to 5.57
[14] Japanese N/A e No 337 e e e
[15] Korean N/A e No 65 e e e
[24] Indian N/A e No 50 e e e
[24] Chinese N/A e No 53 e e e
[24] Japanese N/A e No 42 e e e
[25] African-Caribbean No 48 No 61 e e e
[23] Japanese No 191 Yes 194 CC/TC 2.14 1.32 to 3.45
[26] Caucasian No 279 N/A e e e e
[26] African-American No 193 N/A e e e e
[26] African No 170 N/A e e e e
*Studies in chronological order.
yORs were derived by c2 analysis using published figures and additional unpublished data provided by Dr Vincent Raymond (Personal communication) for study [14].
N/A, not assessed; N, number of patients analysed; POAG, primary open angle glaucoma.
Key points
< Primary open angle glaucoma (POAG) is the second leading
cause of blindness in developed countries, and on the basis of
their pre-treatment intraocular pressures (IOPs), patients are
classified as having either high-tension glaucoma (HTG, IOP
>21.0 mm Hg) or normal-tension glaucoma (NTG, IOP
#21.0 mm Hg).
< Although POAG is a late-onset acquired optic neuropathy, it
has a major genetic basis and it shares striking clinical and
pathological overlap with autosomal dominant optic atrophy
(DOA), which is the result of mutations in the OPA1 gene.
< In this study, we demonstrate a strong association between
two specific OPA1 SNPs (IVS8+4c/t and IVS8+32t/c)
and the risk of developing NTG but not HTG. The high-risk CT/
TT compound genotype conferred a 30-fold increased risk of
disease, supporting a possible role of the Opa1 protein in the
pathophysiology of NTG.
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